Plasma cell leukemia: update on biology and therapy

被引：35

作者：

Mina, Roberto ^{[1
]}

D'Agostino, Mattia ^{[1
]}

Cerrato, Chiara ^{[1
]}

Gay, Francesca ^{[1
]}

Palumbo, Antonio ^{[1
]}

机构：

[1] Azienda Osped Univ Citta Salute & Sci Torino, Myeloma Unit, Div Hematol, Turin, Italy

来源：

LEUKEMIA & LYMPHOMA | 2017年 / 58卷 / 07期

关键词：

Plasma cell leukemia; primary PCL; secondary PCL; autologous stem cell transplantation; novel agents; MULTIPLE-MYELOMA; INTERGROUPE-FRANCOPHONE; GENETIC ABERRATIONS; BORTEZOMIB; SURVIVAL; DEXAMETHASONE; TRANSPLANTATION; LENALIDOMIDE; THALIDOMIDE; CYCLOPHOSPHAMIDE;

D O I：

10.1080/10428194.2016.1250263

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Plasma cell leukemia (PCL) is a rare, but very aggressive, plasma cell dyscrasia, representing a distinct clinicopathological entity as compared to multiple myeloma (MM), with peculiar biological and clinical features. A hundred times rarer than MM, the disease course is characterized by short remissions and poor survival. PCL is defined by an increased percentage (>20%) and absolute number (> 2 x 10(9)/l) of plasma cells in the peripheral blood. PCL is defined as 'primary' when peripheral plasmacytosis is detected at diagnosis, 'secondary' when leukemization occurs in a patient with preexisting MM. Novel agents have revolutionized the outcomes of MM patients and have been introduced also for the treatment of PCL. Here, we provide an update on biology and treatment options for PCL.

引用

页码：1538 / 1547

页数：10

共 66 条

[1] Plasma cell leukemia [J].

Albarracin, Flavio ;

Fonseca, Rafael .

BLOOD REVIEWS, 2011, 25 (03) :107-112

[2] Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients [J].

An, Gang ;

Qin, Xiaoqi ;

Acharya, Chirag ;

Xu, Yan ;

Deng, Shuhui ;

Shi, Lihui ;

Zang, Meirong ;

Sui, Weiwei ;

Yi, Shuhua ;

Li, Zengjun ;

Hao, Mu ;

Feng, Xiaoyan ;

Jin, Fengyan ;

Zou, Dehui ;

Qi, Junyuan ;

Zhao, Yaozhong ;

Tai, Yu-Tzu ;

Wang, Jianxing ;

Qiu, Lugui .

ANNALS OF HEMATOLOGY, 2015, 94 (02) :257-264

[3] Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience [J].

Avet-Loiseau, H. ;

Roussel, M. ;

Campion, L. ;

Leleu, X. ;

Marit, G. ;

Jardel, H. ;

Dib, M. ;

Decaux, O. ;

Lamy, T. ;

Tiab, M. ;

Cony-Makhoul, P. ;

Banos, A. ;

Lepeu, G. ;

Lifermann, F. ;

Macro, M. ;

Kolb, B. ;

Hulin, C. ;

Caillot, D. ;

Traulle, C. ;

Mathiot, C. ;

Royer, B. .

LEUKEMIA, 2012, 26 (01) :158-159

[4] Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia:: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique [J].

Avet-Loiseau, H ;

Daviet, A ;

Brigaudeau, C ;

Callet-Bauchu, E ;

Terré, C ;

Lafage-Pochitaloff, M ;

Désangles, F ;

Ramond, S ;

Talmant, P ;

Bataille, R .

BLOOD, 2001, 97 (03) :822-825

[5] Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma [J].

Bauduer, F .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (04) :996-997

[6] Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia [J].

Benson, Don M., Jr. ;

Smith, Megan K. .

LEUKEMIA & LYMPHOMA, 2007, 48 (07) :1423-1425

[7]

BERNASCONI C, 1989, EUR J HAEMATOL, V43, P76

[8] Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia [J].

Bladé, J ;

Kyle, RA .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (06) :1259-+

[9] Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma [J].

Cavo, M. ;

Pantani, L. ;

Pezzi, A. ;

Petrucci, M. T. ;

Patriarca, F. ;

Di Raimondo, F. ;

Marzocchi, G. ;

Galli, M. ;

Montefusco, V. ;

Zamagni, E. ;

Gamberi, B. ;

Tacchetti, P. ;

Brioli, A. ;

Palumbo, A. ;

Sonneveld, P. .

LEUKEMIA, 2015, 29 (12) :2429-2431

[10] Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia [J].

Chang, Hong ;

Qi, Xiaoying ;

Yeung, Joanna ;

Reece, Donna ;

Xu, Wei ;

Patterson, Bruce .

LEUKEMIA RESEARCH, 2009, 33 (02) :259-262

← 1 2 3 4 5 6 7 →